BRIEF-Biovaxys Technology Files FDA Pre-Ind Meeting Request And Briefing Package For Covid-T
- ByReuters-
March 31 (Reuters) - Biovaxys Technology Corp BIOV.CD :* BIOVAXYS FILES FDA PRE-IND MEETING REQUEST AND BRIEFING PACKAGE FOR COVID-T
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biovaxys Technology Corp (BIOV)
0.130
+0.010(+8.33%)
- Volume:47,003
- Bid/Ask:0.125/0.130
- Day's Range:0.125 - 0.135
BIOV Overview
- Prev. Close
- 0.12
- Day's Range
- 0.125-0.135
- Revenue
- -
- Open
- 0.125
- 52 wk Range
- 0.09-0.65
- EPS
- -0.06
- Volume
- 47,003
- Market Cap
- 12.91M
- Dividend (Yield)
- N/A(N/A)
- Average Volume (3m)
- 58,917
- P/E Ratio
- -
- Beta
- -
- 1-Year Change
- -47.83%
- Shares Outstanding
- 103,280,845
- Next Earnings Date
- -
What is your sentiment on Biovaxys Technology?
or
Market is currently closed. Voting is open during market hours.
Biovaxys Technology Corp News
- BRIEF-BioVaxys Expands Intellectual Property Portfolio
- ByReuters-
March 24 (Reuters) - Biovaxys Technology Corp BIOV.CD :* BIOVAXYS - FILING OF AN INTERNATIONAL PATENT APPLICATION FOR HAPTENIZED VIRAL ANTIGEN VACCINE PLATFORM* BIOVAXYS -...
- BRIEF-BioVaxys Enters Agreement With Inotiv For Preclinical Studies Of Its Covid-T Immunodiagnostic Program
- ByReuters-
March 18 (Reuters) - Biovaxys Technology Corp BIOV.CD :* BIOVAXYS ENTERS AGREEMENT WITH INOTIV TO CONDUCT PRECLINICAL TOXICITY STUDIES FOR ITS COVID-T™ IMMUNODIAGNOSTIC...
Biovaxys Technology Corp Company Profile
Biovaxys Technology Corp Company Profile
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Neutral | Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Sell | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 1.37 | 1.51 | 1.33 | -0.0800 | -5.52% | 178.15K | TSXV | |||
| 2.33 | 2.43 | 2.255 | -0.100 | -4.12% | 2.36M | Toronto | |||
| 9.07 | 9.20 | 8.80 | +0.32 | +3.66% | 5.86K | Toronto | |||
| 122.38 | 122.47 | 119.77 | +2.17 | +1.81% | 577.43K | Toronto | |||
| 94.37 | 94.66 | 93.58 | +0.67 | +0.72% | 779.56K | Toronto | |||
| 135.04 | 135.32 | 132.95 | +1.68 | +1.26% | 3.20M | Toronto | |||
| 1.19 | 1.22 | 0.93 | +0.22 | +22.68% | 962.68K | TSXV | |||
| 0.60 | 0.62 | 0.60 | 0.00 | 0.00% | 4.69K | TSXV | |||
| 0.115 | 0.12 | 0.115 | -0.0100 | -8.00% | 24.50K | TSXV | |||
| 88.47 | 88.78 | 86.92 | +1.34 | +1.54% | 3.38M | Toronto | |||
| 40.96 | 41.03 | 40.63 | +0.29 | +0.71% | 584.02K | Toronto | |||
| 171.46 | 172.71 | 164.63 | +5.75 | +3.47% | 442.11K | Toronto | |||
| 61.11 | 61.35 | 60.51 | +0.40 | +0.66% | 744.89K | Toronto | |||
| 37.30 | 37.30 | 37.30 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 0.52 | 0.55 | 0.52 | -0.08 | -13.33% | 1.00K | Toronto |